{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:30:41Z","timestamp":1790361041392,"version":"4.1.0"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00268","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T13:19:12Z","timestamp":1582895952000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":101,"title":["Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1\/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Victor C.","family":"Kok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"12024","DOI":"10.18632\/oncotarget.7593","article-title":"CD274\/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity","volume":"7","author":"Straub","year":"2016","journal-title":"Oncotarget."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/ijc.23621","article-title":"Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy","volume":"123","author":"Martorelli","year":"2008","journal-title":"Int J Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.4049\/jimmunol.1400794","article-title":"EBV oncogene N-LMP1 induces CD4 T cell-mediated angiogenic blockade in the murine tumor model","volume":"194","author":"Wu","year":"2015","journal-title":"J Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2019.37.15_suppl.6000","article-title":"Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC)","volume":"37","author":"Rischin","year":"2019","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1093\/annonc\/mdx210","article-title":"The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1\/PD-L1 blockade","volume":"28","author":"Foy","year":"2017","journal-title":"Ann Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4143\/crt.2015.249","article-title":"Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer Res Treat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1304337","DOI":"10.1080\/2162402x.2017.1304337","article-title":"Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: a pilot study","volume":"6","author":"Mletzko","year":"2017","journal-title":"Oncoimmunology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.oraloncology.2014.11.014","article-title":"Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma","volume":"51","author":"Ritprajak","year":"2015","journal-title":"Oral Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/1078-0432.CCR-15-1543","article-title":"Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma","volume":"22","author":"Vassilakopoulou","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/s0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/annonc\/mdy411","article-title":"Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial","volume":"29","author":"Colevas","year":"2018","journal-title":"Ann Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejca.2018.12.029","article-title":"Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I\/II expansion cohort","volume":"109","author":"Segal","year":"2019","journal-title":"Eur J Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2018","journal-title":"JAMA Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12885-019-5266-4","article-title":"Phase I\/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma","volume":"19","author":"Bahig","year":"2019","journal-title":"BMC Cancer."},{"key":"B27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.radonc.2019.08.007","article-title":"Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial","volume":"142","author":"Elbers","year":"2019","journal-title":"Radiother Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctro.2018.08.001","article-title":"Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide","volume":"12","author":"Merlano","year":"2018","journal-title":"Clin Transl Radiat Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2217\/fon-2018-0405","article-title":"JAVELIN head and neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer","volume":"15","author":"Yu","year":"2019","journal-title":"Future Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell."},{"key":"B31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00262-019-02302-2","article-title":"Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates","volume":"68","author":"Cassetta","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8633","DOI":"10.18632\/oncotarget.14374","article-title":"Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages","volume":"8","author":"Takahashi","year":"2017","journal-title":"Oncotarget."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1158\/1078-0432.CCR-18-3314","article-title":"Development and validation of a combined hypoxia and immune prognostic classifier for head and neck cancer","volume":"25","author":"Brooks","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0176181","DOI":"10.1371\/journal.pone.0176181","article-title":"Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion","volume":"12","author":"Albacker","year":"2017","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1568812","DOI":"10.1080\/2162402x.2019.1568812","article-title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors","volume":"8","author":"Elkrief","year":"2019","journal-title":"Oncoimmunology."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.09.001","article-title":"Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma","author":"Lalani","year":"2019","journal-title":"Eur Urol Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lungcan.2019.01.017","article-title":"Antibiotics are associated with attenuated efficacy of anti-PD-1\/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer","volume":"130","author":"Zhao","year":"2019","journal-title":"Lung Cancer."},{"key":"B40","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/labinvest.2016.70","article-title":"Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment","volume":"96","author":"Sakakura","year":"2016","journal-title":"Lab Invest."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1002\/ijc.28622","article-title":"Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways","volume":"134","author":"Raber","year":"2014","journal-title":"Int J Cancer."},{"key":"B42","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/1078-0432.Ccr-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00262-018-2225-x","article-title":"Increased Tim-3(+) T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients","volume":"67","author":"Kato","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1158\/1078-0432.CCR-17-1350","article-title":"Novel effector phenotype of Tim-3(+) regulatory T cells leads to enhanced suppressive function in head and neck cancer patients","volume":"24","author":"Liu","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1002\/ijc.30019","article-title":"An adaptive immune response driven by mature, antigen-experienced T and B cells within the microenvironment of oral squamous cell carcinoma","volume":"138","author":"Quan","year":"2016","journal-title":"Int J Cancer."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2016","journal-title":"Oncoimmunology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0175755","DOI":"10.1371\/journal.pone.0175755","article-title":"Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients","volume":"12","author":"Linedale","year":"2017","journal-title":"PLoS ONE."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","article-title":"Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration","volume":"24","author":"Oweida","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.oraloncology.2016.05.008","article-title":"Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells","volume":"58","author":"Concha-Benavente","year":"2016","journal-title":"Oral Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.Cd-17-0593","article-title":"Impaired HLA class i antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"B51","doi-asserted-by":"publisher","first-page":"9281","DOI":"10.1158\/0008-5472.CAN-06-0488","article-title":"HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker","volume":"66","author":"Ogino","year":"2006","journal-title":"Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","author":"Paulson","year":"2018","journal-title":"Nature Commun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00262-010-0961-7","article-title":"Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes","volume":"60","author":"Leibowitz","year":"2011","journal-title":"Cancer Immunol Immunother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/hed.21420","article-title":"Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck","volume":"33","author":"Chikamatsu","year":"2011","journal-title":"Head Neck."},{"key":"B55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature."},{"key":"B56","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cels.2018.05.020","article-title":"IKZF1 enhances immune infiltrate recruitment in solid tumors and susceptibility to immunotherapy","volume":"7","author":"Chen","year":"2018","journal-title":"Cell Syst."},{"key":"B57","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.chom.2013.04.010","article-title":"Iron in infection and immunity","volume":"13","author":"Cassat","year":"2013","journal-title":"Cell Host Microbe."},{"key":"B58","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41586-018-0701-2","article-title":"The metabolite BH4 controls T cell proliferation in autoimmunity and cancer","volume":"563","author":"Cronin","year":"2018","journal-title":"Nature."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0119647","DOI":"10.1371\/journal.pone.0119647","article-title":"Risk of cancer in patients with iron deficiency anemia: a nationwide population-based study","volume":"10","author":"Hung","year":"2015","journal-title":"PLoS ONE."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Investig."},{"key":"B61","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/annonc\/mdy470","article-title":"Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy","volume":"30","author":"Chen","year":"2019","journal-title":"Ann Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e2006134","DOI":"10.1371\/journal.pbio.2006134.","article-title":"KDM5 histone demethylases repress immune response via suppression of STING","volume":"16","author":"Cadwell","year":"2018","journal-title":"PLoS Biology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/ijc.32781","article-title":"STAT1 inhibits T cell exhaustion and myeloid derived suppressor cell accumulation to promote anti-tumor immune responses in head and neck squamous cell carcinoma","volume":"146","author":"Ryan","year":"2019","journal-title":"Int J Cancer."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molimm.2018.01.014","article-title":"Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer","volume":"110","author":"Chrisikos","year":"2019","journal-title":"Mol Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fimmu.2018.00394","article-title":"Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer","volume":"9","author":"Versteven","year":"2018","journal-title":"Front Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/intimm\/dxy050","article-title":"Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells","volume":"30","author":"Mita","year":"2018","journal-title":"Int Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.oraloncology.2011.03.007","article-title":"Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas","volume":"47","author":"Laimer","year":"2011","journal-title":"Oral Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40425-018-0356-4","article-title":"Targeting the TGFbeta pathway with galunisertib, a TGFbetaRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade","volume":"6","author":"Holmgaard","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B71","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature."},{"key":"B72","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature."},{"key":"B73","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00262-004-0652-3","article-title":"Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system","volume":"54","author":"Weber","year":"2005","journal-title":"Cancer Immunol Immunother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1158\/2159-8290.CD-18-0798","article-title":"Overcoming acquired PD-1\/PD-L1 resistance with CD38 blockade","volume":"8","author":"Mittal","year":"2018","journal-title":"Cancer Discov."},{"key":"B77","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1158\/0008-5472.Can-18-0163","article-title":"Human papilloma virus specific immunogenicity and dysfunction of CD8(+) T cells in head and neck cancer","volume":"78","author":"Krishna","year":"2018","journal-title":"Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","article-title":"Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models","volume":"67","author":"Leone","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/ijc.31534","article-title":"Specific blockade CD73 alters the \u201cexhausted\u201d phenotype of T cells in head and neck squamous cell carcinoma","volume":"143","author":"Deng","year":"2018","journal-title":"Int J Cancer."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00018-017-2720-9","article-title":"Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma","volume":"75","author":"Chen","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e1498439","DOI":"10.1080\/2162402x.2018.1498439","article-title":"Treatment-naive HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy","volume":"7","author":"Gameiro","year":"2018","journal-title":"Oncoimmunology."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight."},{"key":"B84","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/1078-0432.Ccr-17-0357","article-title":"Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals","volume":"24","author":"Shayan","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.Cir-18-0725","article-title":"Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun."},{"key":"B87","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.oraloncology.2016.04.005","article-title":"Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma","volume":"57","author":"Kondo","year":"2016","journal-title":"Oral Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00262-017-1968-0","article-title":"Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma","volume":"66","author":"Wu","year":"2017","journal-title":"Cancer Immunol Immunother."},{"key":"B89","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.26355\/eurrev_201906_18193","article-title":"MiR-373 promotes proliferation and metastasis of oral squamous cell carcinoma by targeting SPOP","volume":"23","author":"Zhang","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/2159-8290.CD-14-1205","article-title":"Therapeutic insights from genomic studies of head and neck squamous cell carcinomas","volume":"5","author":"Hammerman","year":"2015","journal-title":"Cancer Discov."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00262-012-1321-6","article-title":"Implication of the beta2-microglobulin gene in the generation of tumor escape phenotypes","volume":"61","author":"Bernal","year":"2012","journal-title":"Cancer Immunol Immunother."},{"key":"B92","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neo.2017.02.004","article-title":"A Novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment","volume":"19","author":"Mediavilla-Varela","year":"2017","journal-title":"Neoplasia."},{"key":"B93","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1158\/2159-8290.CD-14-0341","article-title":"Targeting cancer-derived adenosine: new therapeutic approaches","volume":"4","author":"Young","year":"2014","journal-title":"Cancer Discov."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00262-011-1040-4","article-title":"Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity","volume":"60","author":"Hausler","year":"2011","journal-title":"Cancer Immunol Immunother."},{"key":"B95","doi-asserted-by":"publisher","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B96","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev."},{"key":"B97","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5.","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41416-019-0449-y","article-title":"Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma","volume":"120","author":"Rasmussen","year":"2019","journal-title":"Br J Cancer."},{"key":"B99","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science."},{"key":"B100","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.oraloncology.2019.07.020","article-title":"APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma","volume":"96","author":"Faden","year":"2019","journal-title":"Oral Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.oraloncology.2017.09.002","article-title":"Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma","volume":"74","author":"Faden","year":"2017","journal-title":"Oral Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gr.241141.118","article-title":"Human papillomavirus and the landscape of secondary genetic alterations in oral cancers","volume":"29","author":"Gillison","year":"2019","journal-title":"Genome Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"P80","DOI":"10.1186\/2051-1426-3-s2-p80","article-title":"Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors","volume":"3","author":"Ayers","year":"2015","journal-title":"J Immunother Cancer."},{"key":"B104","doi-asserted-by":"publisher","first-page":"7024","DOI":"10.1158\/1078-0432.CCR-19-1372","article-title":"Noninvasive detection of microsatellite instability and high tumor mutation burden[[Inline Image]] in cancer patients treated with PD-1 blockade","volume":"25","author":"Georgiadis","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"98811","DOI":"10.1172\/jci.insight.98811","article-title":"Frameshift events predict anti-PD-1\/L1 response in head and neck cancer","volume":"3","author":"Hanna","year":"2018","journal-title":"JCI Insight."},{"key":"B106","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/annonc\/mdl048","article-title":"Microsatellite instability and methylation of the DNA mismatch repair genes in head and neck cancer","volume":"17","author":"Demokan","year":"2006","journal-title":"Ann Oncol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"22614","DOI":"10.1038\/srep22614","article-title":"Microsatellite alteration in head and neck squamous cell carcinoma patients from a betel quid-prevalent region","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep."},{"key":"B108","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science."},{"key":"B109","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/s1470-2045(16)30066-3.","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.2016.34.15_suppl.3034","article-title":"Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System","volume":"34","author":"Wallden","year":"2016","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T14:01:18Z","timestamp":1582898478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":111,"alternative-id":["10.3389\/fonc.2020.00268"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00268","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]},"article-number":"268"}}